Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. - Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; et al. (Arthritis & rheumatology (Hoboken, N.J.), 2023)